Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,001–2,100 of 3,704
Research Priorities and Future Directions in Cardio-Oncology
Mszar, R., Ali, A., Hull, S. C., Ferrucci, L. M., Baldassarre, L. A., Khera, R., Irwin, M. L., & Clasen, S. C. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01366-w · Cited by 5
Sun, Y., Xia, Y. Y., Ge, W., & Li, Q. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178523 · Cited by 3
Gao, F., Yuan, M., Mi, N., Peng, D., Dong, R., Hu, W., Dong, X., Chen, J., Xu, Y., Zhou, J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70429 · Cited by 4
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 5
Lipedema: pathophysiological insights and therapeutic strategies – An update for dermatologists
Dini, T. D., Birck, M. S., Saalfeld, R. M., Macedo, C. L. D., & Bagatin, E. (2026) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501270 · Cited by 12
Tsatsaki, C., Dimakopoulos, G., Florentin, M., Mangiorou, E., Milionis, H. J., Liamis, G. L., Doumas, M. N., Kotsa, K., Barkas, F., & Koufakis, T. (2026) · HORMONES · doi:10.1007/s42000-025-00755-y · Cited by 3
Tentolouris, A., Siafarikas, C., Ntanasis‐Stathopoulos, I., Anastasiou, I. A., Kalara, E., & Briasoulis, Α. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.01.003 · Cited by 3
Malik, M. H. A., Amjad, H., Malik, K., Saleem, M. S., Akhtar, S., Paracha, M., Abid, M., Shafi, N., Raza, A. A., Samadi, A., et al. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71929 · Cited by 3
“Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has been shown to produce marked improvements in glycemic control and weight reduction in type 2 diabetes [5].”
Hierholzer, J. D., Benson, H., Ewida, H. A., & Ahmed, M. S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168172 · Cited by 4
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Berry, K. A. Z., Garfield, A., Macias, E., Zarini, S., Bowen, S., Cree‐Green, M., Snell‐Bergeon, J. K., Bodkin, S. G., & Bergman, B. C. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag018 · Cited by 5
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
Patrizio, A., Mauguen, A., Fagin, J. A., Farooki, A., Fish, S. A., Flory, J., Newman, S. K., Presswala, L. S., Sabra, M. M., Tuttle, R. M., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag051 · Cited by 5
Corrêa, L. M. D. A., Mazur, G. R., Santiago, C. B. G., Dante, L. E., Marco, P. S., & Ferrés, P. B. S. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101003 · Cited by 2
Schmidt, P. H. S., de Souza, V. S. N., Machado, L. G., Rodrigues, J. V. A., da Cruz, J. V. R., de Souza, L. S. N., dos Santos, B. E., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70529 · Cited by 8
“31,32 However, these findings reflect perceived rather than objectively measured physical function.”
Nielsen, C. K., Pálsson, T. G., Forman, J. L., Lukacova, M., Jensen, B. A., Mathiesen, D. S., Englund, A., Gether, I. M., Johansen, N. J., Pedersen, M. G., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103801 · Cited by 3
“11,12 All metabolic assessments were conducted under fasting conditions; hence, potential postprandial effects of dapiglutide on glucose or insulin dynamics could not be evaluated.”
Puga, T. B., Box, M. W., Jen, A., Liu, Y., & Riehl, J. T. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.02.002 · Cited by 2
Sattar, N. A., Lee, C. J., Srinath, R., Schauer, P. R., Wang, H., Falcón, B. L., HE, X., Stefański, A., & Plat, A. W. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101454 · Cited by 6
“…cholesterol; MTD = maximum tolerated dose; N = total number of participants; NS = not significant; SE = standard error; VLDL-C = very-low-density lipoprotein cholesterol. fasting glucose, glycated hemoglobin (HbA1c), vitals, blood pressure, and lipid profile were assessed for both trials [8,11].”
InfluentialSelf-citationLuca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Iglesias, P., Nobre, E. L., Hanzu, F. A., Schweizer, J. R. D. O. L., Valero, L. M., Araujo-Castro, M., Luna, A. C., Albacete, F. J., Villar‐Taibo, R., & Reinke, M. (2026) · Endocrine · doi:10.1007/s12020-026-04587-7 · Cited by 2
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“Clinical trials show that using tirzepatide, which targets two incretin receptors, leads to significant and lasting weight loss in adults with obesity [11].”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
MetALD at the crossroads of metabolic and alcohol-related liver disease
Ayares, G., Díaz, L. A., Arab, J. P., & Arrese, M. A. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.008 · Cited by 3
GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 4
“Methodological quality was independently assessed by the same reviewer pairs using the Cochrane Risk of Bias 2.0 tool [5, 6].”
InfluentialRao, P. P. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100694 · Cited by 3
Prasad, A., Arora, A., Arora, A., Vaid, J., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70515 · Cited by 3
Reprogramming the mitochondrial–circadian energy code with incretins
Nisoli, E., Ragni, M., Ruocco, C., & Valerio, A. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.02.011 · Cited by 2
GLP-1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum Periods
Porterfield, F., Ogunwole, S. M., Maya, J., & Stanford, F. C. (2026) · Pediatric Drugs · doi:10.1007/s40272-026-00746-5 · Cited by 3
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
Arslan, S., & Aydin, A. (2026) · Academia oncology. · doi:10.20935/acadonco8234 · Cited by 2
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Retatrutide-Induced Intractable Diarrhea
Komolafe, O. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1218 · Cited by 2
Wang, Z., Huang, W., Rasmussen, R. S., Horowitz, M., Jones, K. L., Rayner, C. K., Xie, C., & Wu, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70735 · Cited by 3
“However, the recently appreciated substantial metabolic benefits of dual GLP-1/GIP receptor agonism (e.g., tirzepatide) [8] and GIP receptor antagonism [9] have renewed interest in GIP actions in T2D.”
Genetics reveal why people respond differently to GLP-1 weight-loss drugs
Loos, R. J. F. (2026) · Nature · doi:10.1038/d41586-026-00905-1 · Cited by 2
Chen, F., Dall, T. M., Ferguson, C. C., Sapra, T., Hafida, S., Livingston, T., ElSayed, N. A., Moody, A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0004 · Cited by 2
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients
Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera‐Diaz, A., Jelić, S., St‐Onge, M., & Cai, Y. (2026) · Otolaryngology · doi:10.1002/ohn.70231 · Cited by 2
Rampy, J., Torres-Manzo, A. P., Hoffsmith, K., Loberg, M. A., Sheng, Q., Salas-Lucia, F., Bianco, A. C., Drigo, R. A. E., Wang, H., Weiss, V. L., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194207 · Cited by 2
“This promising therapeutic approach calls for deeper investigation in the midst of the ever-worsening obesity epidemic, especially given that not all patients respond to GLP-1 receptor agonists (86).”
Baig, S. J., Bhasker, A. G., Parmar, C. D., Wadhawan, R., Shah, S., Shaikh, S. S., Kapoor, N., Das, S., Harikumar, K., Kotwal, N., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08669-3 · Cited by 3
“The SURMOUNT 1 trial [24 ] demonstrated mean weight loss of − 15.0% with tirzepatide 5 mg weekly, − 19.5% with 10 mg weekly, and − 20.9% with 15 mg weekly at 72 weeks compared to − 3.1% with placebo.”
InfluentialGunasekaran, P., Inban, P., Agrawal, A., Thai, A., Aravazhi, P. S., Tariq, H., Prajjwal, P., & John, J. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102113 · Cited by 3
Vecchiato, M., Palermi, S., Zámodics, M., Babity, M., Eftekhari, M., Ryali, R., Luk, J., Taseh, A., Ashkani‐Esfahani, S., Merkely, G., et al. (2026) · Sports Medicine - Open · doi:10.1186/s40798-026-01026-9 · Cited by 5
“These cardioprotective effects appear mediated by weight reduction, improved endothelial function, and anti-inflammatory actions [108–111].”
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
“In patients with obesity without T2DM, the SURMOUNT-1 study reported an average weight loss of 17.8% at 72 weeks [36].”
InfluentialShould Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Hofstad, M., & Abreu, I. D. (2026) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000920 · Cited by 2
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 3
“The most effective agent in this class on the market so far is tirzepatide, a dual gastric inhibitory polypeptide (GIP) and GLP-1 agonist, leading to a mean weight loss of 21% at maximal dose over 72 weeks [20].”
Friedman, A. N., Oultache, I., & Hovey, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.037 · Cited by 3
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“…agonists are generally well tolerated; however, gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are the most frequently reported, particularly during the initial treatment phase (Wilding et al., 2021; Wharton et al., 2022; Jastreboff et al., 2022; Ghusn and Hurtado, 2024).”
Napoli, M. D., Morton, K., Evensky, C. H., Yoshida, C. T., Baimas‐George, M. R., Castle, R., Kennealey, P. T., Nydam, T. L., & Choudhury, R. A. (2026) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2026.117027 · Cited by 2
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“In the absence of direct head-to-head trials, the most reasonable interpretation is that orforglipron may become the preferred oral incretin option for patients who want greater efficacy than traditional oral agents but are unwilling to initiate injections [37,53].”
InfluentialKaiser, A. M., Carmichael, H., Lee, L., Aminpour, N., Alkhamesi, N. A., Ore, A. S., Dantu, S., Bonilla, E. J., deBeche-Adams, T., Krane, M. K., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-12878-3 · Cited by 2
Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
Cheng, P.-L., & Chang, H. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113333 · Cited by 8
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
Trott, M., Arnautovska, U., Johnston, D. J. G., Ritchie, G., & Siskind, D. J. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12001 · Cited by 3
“18 Furthermore, studies examining tirzepatide have yielded substantial weight loss exceeding 15% across similar time frames, 19 with comparative effectiveness studies concluding that tirzepatide is superior to semaglutide in terms of weight loss.”
Patient preferences for pharmacological treatments for obesity: The VOICE study
Houle, C. R., Gelhorn, H. L., Cutts, K. N., Samuelson, A., & Xavier, N. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100278 · Cited by 4
“While recently approved incretin-based therapies have emerged as safe and efficacious options for the treatment of overweight or obesity [13,14], historical challenges contribute to ongoing underutilization of pharmacotherapy in obesity management, and long-term persistence continues to be a…”
Pereira, L. V., Coutinho, M. D. A. P., Hortiz, D., Xavier, A. L., & Lima, R. P. A. (2026) · Nutrients · doi:10.3390/nu18111725 · Cited by 4
“These agents are primarily indicated for individuals with obesity or overweight complicated by metabolic comorbidities— including insulin resistance, type 2 diabetes, and cardiovascular disease—especially when behavioral interventions alone prove insufficient [44].”
Kherad, O., Martel, M., Afif, W., Bessissow, T., Barkun, A. N., & Restellini, S. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103640 · Cited by 2
“…reported in phase III trials of GLP-1 RAs in non-IBD populations in whom semaglutide and tirzepatide achieved mean weight losses of approximately 15% and up to 21%, respectively, 42 43 the outcomes are consistent with prior reports of liraglutide yielding a 63% response rate for ≥5% weight loss.”
A Hormone Cell Atlas maps the human endocrine system at cellular resolution
Fei, L., Huang‐Doran, I., Lawler, K., Yu, Y., Pett, J. P., Méndez-Acevedo, K. M., Shah, D., Margalef-Rieres, J., Pohlman, J. S., Çakır, B., et al. (2026) · Yearbook of pediatric endocrinology · doi:10.1126/science.aeb2672 · Cited by 6
Sanger, G. J., Golding, J. F., & Andrews, P. L. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2682294 · Cited by 2
“However, tirzepatide dose-dependently causes gastrointestinal adverse events, including nausea and vomiting, of ‘mild-to-moderate severity’ [180,181] and does not appear to have an obviously lower odds ratio for reporting nausea or vomiting [182].”
Fabi, S. G., Yoo, J. Y., Kaufman-Janette, J. A., Dayan, S., Boyd, C., Sangha, S., & Ashourian, N. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005166 · Cited by 10
Wu, J., Lin, L., Sun, J., Yu, W., Yuliani, F. S., & Lin, S. (2026) · Obesity · doi:10.1002/oby.70218 · Cited by 3
Yang, Z., Xu, Y., Du, H., Liu, W., Chen, H., Liu, D., Zhang, L., & Wang, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70966 · Cited by 9
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs, including exenatide, liraglutide and semaglutide) are increasingly recognised as promising therapeutic options for overweight/ obese women with PCOS, given their ability to induce significant weight loss and enhance insulin sensitivity [5–8].”
Gudzune, K. A., Perreault, L., Apovian, C. M., Aroda, V. R., Aronne, L. J., Fitch, A., Fitzpatrick, S. L., Garvey, W. T., Kahan, S. I., Khunti, K., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci26-0003 · Cited by 13
Self-citationGisondi, P., & Girolomoni, G. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01812-z · Cited by 3
“The significant reductions in body weight, BMI and waist-to-hip ratio observed in our cohort are consistent with the known pharmacological profile of tirzepatide and closely mirror the magnitude of weight loss reported in clinical trials involving individuals with obesity without psoriasis [7].”
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
Self-citationLeslie, D. B., Steffen, B. T., Wise, E., Steffen, L. M., Kopacz, K., Ruanpeng, D., Jacobs, D. R., & Ikramuddin, S. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00030-6 · Cited by 3
Yang, M., & Liang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839620 · Cited by 5
“Dual and triple incretin receptor agonists, including GLP-1/GIP and GLP-1/GIP/glucagon receptor agonists, represent a major pharmacological advance (129, 130).”
Fletcher, R. A., Conrad, N., Rockenschaub, P., Logothetis, S. B., Neuen, B. L., Chalmers, F., Dalakoti, M., Raffetti, E., Denaxas, S., Khunti, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00120-8 · Cited by 7
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Self-citationBile acids: New regulators of the cardiometabolic crosstalk
Wolf, S., Nagler, M., & Osto, E. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108320 · Cited by 6
Curtis, L. H., Arterburn, D. E., Toh, S., Guo, J. S., Hernán, M. Á., Iturralde, E., Jastreboff, A. M., Lewis, K. H., Lund, J. L., Maciejewski, M. L., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00202 · Cited by 2
Self-citationGLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Damhof, M. A., van Bruggen, F. H., & Roon, E. N. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71075 · Cited by 3
“…mean weight reductions of approximately 15% with semaglutide and up to or exceeding 20% with tirze-patide, a dual glucose-dependent insulinotropic polypeptide/ GLP-1 receptor agonist (GIP/GLP-1RA), representing an unprecedented degree of efficacy for anti-obesity pharmacotherapy [1, 2].”
Noureddin, M., Dunn, W., Patil, R., Desai, D., Puskoor, R., Shin, J., To, D., BELL, A. C., Lee, D. R., Lin, Y.-H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00130-5 · Cited by 2
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
Lewis, J. E., Montaner, M., Nuzzaci, D., James-Okoro, P.-P., Harada, N., Inagaki, N., Dodson, W. S., Knerr, P. J., Douros, J. D., Gribble, F. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01575-z · Cited by 6
“Both GIPR co-agonism (as in tirzepatide) and GIPR antagonism (as in MariTide, a bispecific hybrid molecule comprising two GLP-1R agonist peptides conjugated to a monoclonal anti-GIPR antagonistic antibody) are effective in treating people living with obesity 2,3,22 .”
Sleep and obesity—known interactions and open questions
Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O. A., Kumar, A., & Malhotra, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00130-7 · Cited by 3
“…~ 1 year before weight plateaus with both bariatric surgery and incretin-based pharmacotherapy) [15, 22], its effect on OSA severity on an individual level is variable [16, 59], and a substantial fraction of patients have sleep apnea in the absence of obesity—especially in community cohorts [60].”
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Harnessing the Incretin System with Multi-Agonists
Whyte, M., Heald, A. H., & Field, B. C. T. (2022) · EMJ Innovation · doi:10.33590/emjinnov/10115628 · Cited by 2
Integrating semaglutide into obesity management – a primary care perspective
Kyrillos, J. V., SKOLNIK, N., Mukhopadhyay, B., & Pennings, N. J. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2149964 · Cited by 4
Primary Care Physicians’ Perceptions of the Effects of Being Overweight on All-cause Mortality
Mathur, M. B., & Mathur, V. S. (2023) · Epidemiology · doi:10.1097/ede.0000000000001590 · Cited by 1
The Case for Bariatric Surgery in Patients with Class 1 Obesity
Scott, A. W., Leslie, D. B., Ikramuddin, S., Dutta, N., Amateau, S. K., & Wise, E. S. (2023) · Current Surgery Reports · doi:10.1007/s40137-023-00355-y · Cited by 2
“9% respective percent reduction in total body weight over 72 weeks [85].”
BackgroundMolecular Pathology and Therapeutic Strategies of Type 2 Diabetes
Liao, H. Z., Liang, Y., Wang, Y., & Liang, C. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230320162753 · Cited by 4
Baden, C. S., Andersen, J. T., Christensen, M., & Gade, C. (2023) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000067 · Cited by 3
The Physiological Regulation of Body Fat Mass
Sumithran, P. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.003 · Cited by 5
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Fang, H., Niu, B., & Chen, Q. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230416153301 · Cited by 3
Top studies of 2022 relevant to primary care: From the PEER team
Perry, D., Moe, S. S., Thomas, B., Lindblad, A. J., Kirkwood, J. E. M., Falk, J., Potter, J., Paige, A., & Allan, G. M. (2023) · Canadian Family Physician · doi:10.46747/cfp.6905325 · Cited by 3
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Aberle, J., Forst, T. M., Heitmann, E., Görgens, S. W., & Seufert, J. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2078-9491 · Cited by 4
“Kürzlich wurden überdies die ersten Ergebnisse für Tirzepatid als Mittel zur Gewichtsabnahme bei Menschen mit Adipositas aus der SURMOUNT-1-Studie veröffentlicht [27].”
BackgroundEndoluminal bariatric and metabolic therapies: state-of-the-art
Bakheet, N. G., Badurdeen, D., Sartoretto, A., & Kumbhari, V. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000967 · Cited by 2
Incretin Analogs for Weight Management in Adults Without Diabetes
Lobkovich, A. M., Kale-Pradhan, P. B., & Lipari, M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190089 · Cited by 4
Jakicic, J. M., & Rogers, R. J. (2023) · Nutrients · doi:10.3390/nu15153452 · Cited by 2
“While there is a growing focus on the use of anti-obesity medications, which have been shown to be highly efficacious for weight loss [3], there remains a need to continue to focus on lifestyle factors that contribute to body weight regulation.”
BackgroundPreoperative Patient Evaluation
Villasenor, M., & Selzer, A. R. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.08.004 · Cited by 2
Strategies for Long-Term Weight Loss and Maintenance
Seo, Y. B. (2023) · Korean Journal of Family Practice · doi:10.21215/kjfp.2023.13.3.128 · Cited by 2
Raddatz, D. (2023) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-023-00170-3 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Beyond pounds: What else could be lost?
Idrees, T., & Umpierrez, G. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108649 · Cited by 2
“NASH-Worldwide the Commonest Aetiology of Liver Cirrhosis”- a Review Article
Jannat, S. N. E., Islam, M. M. S. U., Haque, M. M., Imam, I., & Ahmed, D. S. (2023) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v2i2.69844 · Cited by 2
“Tirzepatide: It reduces steatosis, improve insulin sensitivity, causes significant weight loss, it may causes gall stone related pancreatitis 123, 124 .”
Background2023 Update in ambulatory general internal medicine
Alexander, J. T., Singh, S. K., Shah, S. D., Lambert, B., & Smith, J. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23056 · Cited by 2
“33,34 Tirzepatide once weekly promotes weight loss in patients without diabetes Jastreboff et al 35 examined whether tirzepatide, a once-weekly subcutaneous injection drug with agonist activity at glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, was safe and effective for weight loss…”
BackgroundFerrera, A., Gallo, G., & Volpe, M. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00626-4 · Cited by 2
“New compounds such as liraglutide and semaglutide, two Glucagon Like peptide-1 receptor agonists (GLP-1RA), originally developed to treat diabetes, have been successfully used to treat obesity achieving persistent weight loss in diabetic and non-diabetic individuals [9–12].”
BackgroundAberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6797 · Cited by 2
“More than half of patients taking tirzepatide 10 mg and 15 mg (55 % and 63 %, respectively) lost at least 20 % of their body weight, compared to only 1.3 % with place - bo [24].”
Influential
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.